Atea Pharmaceuticals, Inc. — Director's Dealing 2024

Sep 20, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Atea Pharmaceuticals, Inc. (AVIR)
CIK: 0001593899
Period of Report: 2024-09-17

Reporting Person: Sommadossi Jean-Pierre (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-09-17	Common Stock	S	33941	$4.0458	Disposed	5890053	Indirect
2024-09-18	Common Stock	S	22187	$4.0325	Disposed	5867866	Indirect
2024-09-19	Common Stock	S	1841	$4.0019	Disposed	5866025	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	116557	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.14. The Reporting Person undertakes to provide Atea Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.0975. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.01. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.